G. Steve Burill

Burrill & Company, the life sciences investment firm in San Francisco, reviews the biomedical landscape from financial and regulatory trends, to forecasts about diagnostics, bioinformatics, healthcare, digital health to pharmaceuticals, biofuels, and agricultural biotech.  Among these things, Steve Burrill expects “Diagnostics will grab an increasing portion of healthcare spending in 2012 driven by the approval of new companion diagnostics, the growth of predictive diagnostics, and the emergence of an increasing number of point-of-care diagnostics.” He also foresees major investment in new ways to harness genomics.  MORE

Image Credit:  Burrill & Company